How can you compare CAR-T with later-line treatments in Shanghai after large B-cell lymphoma relapses?
Bring your pathology subtype, the date you finished first-line treatment, your response to each treatment, and your latest PET/CT results. For people whose disease is refractory to first-line treatment or relapses soon afterward, the hematology team may discuss certain CAR-T products earlier. People who relapse later and can tolerate intensive treatment can still be assessed for autologous transplantation after salvage therapy. The treatment sequence depends on the specific subtype, time to relapse, overall health, and which treatment can be arranged in time for the current disease situation.
Key points The same CAR-T product originally developed in China, inaticabtagene autoleucel, is also used for B-cell acute lymphoblastic leukemia. Large B-cell lymphoma has its own approved treatment-line requirements; leukemia data cannot be used to estimate your individual treatment response.
Put your relapse timeline and pathology on the same page
Bring your original pathology diagnosis, immunohistochemistry results, samples from new lesions, and earlier and later scans. If a suspicious lesion looks different from the original disease, your doctor may first recommend another biopsy. Record the date of the last dose of your initial treatment, when you achieved your best response, and the date relapse was first confirmed.
For diffuse large B-cell lymphoma that is primary refractory or relapses within 12 months after first-line treatment, randomized studies support certain specific CAR-T products as second-line treatment. People who relapse after more than 12 months, respond to salvage therapy, and can tolerate intensive treatment may also choose salvage therapy followed by autologous hematopoietic stem cell transplantation. Ask your doctor to explain which evidence applies to you and which products match your treatment line under their approvals in China.
Who can discuss inaticabtagene autoleucel
In November 2025, China approved the CD19-targeted inaticabtagene autoleucel (源瑞达) for adults with relapsed or refractory large B-cell lymphoma after at least two lines of systemic treatment. Clearly list each treatment regimen, your response to it, and why it was stopped, particularly noting any previous CD19-targeted treatment. Have the hematopathology team check the subtype, target information from the latest sample, and whether another biopsy is needed.
The drug was first approved in China in 2023 for adult B-ALL. If someone provides leukemia remission rates, ask instead about evidence in lymphoma patients at the same treatment stage, the follow-up duration, and comparable alternatives.
How disease is controlled while the cells are being prepared
Both autologous transplantation and CAR-T require cell collection, but the purpose of collection and the subsequent treatment differ. CAR-T involves collecting T cells to be modified; autologous transplantation involves collecting stem cells to restore blood cell production after intensive treatment. While waiting for CAR-T, some patients need bridging medication or local radiotherapy to control the disease, followed by lymphodepleting pretreatment according to the protocol shortly before infusion.
If intensive treatment is unsuitable, you can also discuss applicable antibody therapies, targeted therapies or other later-line drugs, registered clinical studies, and symptom control. If lesions compress an organ or grow rapidly while you are waiting, or if an infection develops, prioritize contacting your current doctor so the two centers can coordinate urgent care and subsequent options.
Get a cost estimate for each stage before traveling to Shanghai
Inaticabtagene autoleucel: CNY 999,000 per patient dose, as a reference cost for the cell therapy product. Pathology review and imaging, apheresis, bridging treatment, lymphodepleting pretreatment, hospitalization, treatment for infection or critical illness, and return follow-up visits are charged separately. Before paying, clarify which items are included and how charges will be settled if the infusion cannot take place.
Shanghai Jiao Tong University School of Medicine has described the multidisciplinary assessment and follow-up provided by Ruijin Hospital's lymphoma and CAR-T team. You can first ask prospective treating centers such as Ruijin Hospital to review your records, confirm the product, an available assessment date, and arrangements for the interim period, and then finalize your travel plans. If you develop fever, difficulty breathing, or changes in awareness or speech after infusion, seek medical attention immediately according to the emergency instructions.
Frequently asked questions
Is CAR-T always necessary at the first relapse?
The timing of relapse and sensitivity to treatment need to be considered together. Some products have evidence supporting earlier-line use, while others require at least two prior lines of systemic treatment.
What if I originally had follicular lymphoma and the lesions suddenly start growing very quickly?
Ask the hematology team to assess whether a tissue sample is needed to confirm transformation. If pathology shows transformation to large B-cell lymphoma, the treatment sequence and product selection will change accordingly.
Can a CAR-T product suggested by a doctor abroad also be used directly in Shanghai?
Send the generic name, treatment line, and pathology subtype to the Shanghai center so it can check them against the approved label in China and confirm whether it can offer an assessment for that product.
Are bridging treatment and lymphodepleting pretreatment the same?
Bridging treatment controls lymphoma while you wait for the cells to be prepared; lymphodepleting pretreatment involves medication given according to the protocol in preparation for infusion. Ask the center separately about the dates, treatment location, and costs for each.
Can I return to my home country immediately after infusion?
First confirm the monitoring period, caregiver requirements, and near-term follow-up appointments with the center. Your local doctor can then take over follow-up of blood counts, infections, and treatment response. Your travel date will depend on your recovery.